Table 6. Comparison of grade 3–5 AEs between the camrelizumab group and SoC group.

3–5 AEs	Camrelizumab group (n=28), n (%)	SoC group (n=13), n (%)	P value
Bone marrow suppression	5 (17.9)	2 (15.4)	0.845
Neurotoxicity	2 (7.1)	1 (7.7)	0.950
Nausea and vomiting	2 (7.1)	1 (7.7)	0.950
Stomatitis	1 (3.6)	1 (7.7)	0.569
Hand-foot syndrome	1 (3.6)	0	0.490
RCCEP	1 (3.6)	0	0.490
Rash	2 (7.1)	0	0.323
Abnormal liver function	3 (10.7)	0	0.220
Hypothyroidism	1 (3.6)	0	0.490

AEs, adverse events; SoC, standard-of-care; RCCEP, reactive cutaneous capillary endothelial proliferation.